INBX - NASDAQ
Inhibrx Biosciences, Inc.
$91.47
-2.3%Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
At a Glance
Live SnapshotInhibrx Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
Inhibrx Biosciences, Inc. Balance Sheet
INBX • NASDAQ
| Inhibrx Biosciences, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
124.2M | 152.6M | 277.9M | 273.9M | 131.3M | 128.7M | 11.5M | 2.1M | 13.5M | 20M | |
124.2M | 152.6M | 277.9M | 273.9M | 131.3M | 128.7M | 11.5M | 2.1M | 13.5M | 20M | |
177K | 420K | 778K | 257K | 878K | 615K | 438K | 690K | 696K | 0.0 | |
0.0 | 397K | 778K | 257K | 878K | 615K | 438K | 0.0 | 0.0 | 0.0 | |
177K | 23K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 690K | 696K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -878K | -129.3M | 3.2M | 2.3M | 999K | 0.0 | |
8.2M | 6.6M | 15.9M | 6.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
238K | 816K | 728K | 181K | 7.8M | 132.2M | 376K | 553K | 276K | 383K | |
132.8M | 160.4M | 295.4M | 280.5M | 139.1M | 132.2M | 15.6M | 5.7M | 15.4M | 20.4M | |
NON-CURRENT ASSETS | ||||||||||
9.3M | 13.5M | 9.4M | 7.2M | 9.5M | 11.3M | 10.7M | 2.6M | 1.8M | 864K | |
4.4M | 6.8M | 3.2M | 3.2M | 1.8M | 245K | 245K | 1.7M | 0.0 | 0.0 | |
13.6M | 20.4M | 12.5M | 10.4M | 11.3M | 11.6M | 10.9M | 4.3M | 1.8M | 864K | |
146.5M | 180.8M | 307.9M | 290.9M | 150.5M | 143.7M | 26.5M | 10M | 17.2M | 21.3M | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
5.9M | 9.2M | 11M | 8.3M | 9.1M | 13.5M | 3.1M | 6.5M | 775K | 167K | |
5.9M | 9.2M | 11M | 8.3M | 9.1M | 13.5M | 3.1M | 6.5M | 775K | 167K | |
7.5M | 22.2M | 36.8M | 3.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.3M | 1.6M | 0.0 | 1.9M | 1.7M | 1.5M | 4.7M | 5.9M | 5.2M | 4.3M | |
0.0 | 0.0 | 2.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 166K | 2M | 3.1M | 7.9M | 1.6M | 2.6M | 0.0 | |
18.1M | 7.7M | 6.5M | 13.9M | 9.6M | 13.4M | 4.8M | 2.1M | 372K | 856K | |
33.8M | 40.7M | 56.3M | 27.6M | 22.5M | 31.4M | 20.6M | 16.2M | 8.9M | 5.3M | |
NON-CURRENT LIABILITIES | ||||||||||
100.6M | 0.0 | 207M | 202.1M | 70.5M | 36M | 37.1M | 3.6M | 9.5M | 14.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 110K | 737K | 1M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -6.7M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 5M | 180K | 68.1M | 47.9M | 21.3M | 92K | |
104.7M | 6.5M | 208.1M | 205.2M | 75.6M | 36.9M | 99.5M | 51.4M | 30.7M | 14.8M | |
4.1M | 6.5M | 3.2M | 3.2M | 0.0 | 0.0 | 7.8M | 0.0 | 0.0 | 0.0 | |
138.5M | 47.2M | 264.4M | 232.8M | 98.1M | 68.3M | 120.1M | 67.6M | 39.7M | 20M | |
SHAREHOLDERS' EQUITY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 150.5M | 143.7M | 59.5M | 47.5M | 0.0 | 0.0 | |
1K | 1K | 5K | 4K | 4K | 4K | 2K | 3K | 0.0 | 0.0 | |
254.2M | 239.7M | 657.2M | 430.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-246.2M | -106.1M | -613.7M | -372.4M | -227.1M | -145.4M | -69.3M | -17.9M | -28.8M | -9.2M | |
0.0 | 0.0 | 0.0 | 0.0 | -150.5M | -143.7M | -59.5M | -1.7M | -1M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 279.5M | 220.8M | -24.3M | -85.6M | 1M | 0.0 | |
8M | 133.6M | 43.5M | 58.1M | 52.4M | 75.5M | -93.6M | -57.6M | -28.8M | -9.2M | |
8M | 133.6M | 43.5M | 58.1M | 52.4M | 75.5M | -93.6M | -57.6M | -22.4M | 1.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.4M | 10.5M | |
SUMMARY | ||||||||||
146.5M | 180.8M | 307.9M | 290.9M | 150.5M | 143.7M | 26.5M | 10M | 17.2M | 21.3M | |
107M | 8M | 210.1M | 207.1M | 72.1M | 37.5M | 41.7M | 9.5M | 14.7M | 18.9M | |
-17.2M | -144.5M | -67.8M | -66.8M | -59.2M | -91.2M | 30.2M | 7.4M | 1.2M | -1.1M | |
14,485,016 | 14,485,016 | 14,485,016 | 14,485,016 | 14,485,016 | 14,485,016 | 14,485,016 | 14,485,016 | 14,485,016 | 14,485,016 |
SEC Filings
INBX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 16, 2025 | 2025 |
Related Guides
Continue your INBX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.